On Friday, Following U.S. Stocks were among the “Top Gainers”: Carmike Cinemas, (NASDAQ:CKEC), Cytori Therapeutics (NASDAQ:CYTX), CorMedix (NYSEMKT:CRMD), Whiting Petroleum (NYSE:WLL)
Carmike Cinemas, Inc.(NASDAQ:CKEC), with shares inclined 9.73%, closed at $34.05.
Cytori Therapeutics Inc(NASDAQ:CYTX), with shares jumped 4.35%, settled at $1.20.
CorMedix Inc.(NYSEMKT:CRMD, with shares climbed 4.35%, and closed at $8.40.
Whiting Petroleum Corp(NYSE:WLL), surged 4.28%, and closed at $40.00.
Latest NEWS regarding these Stocks are depicted underneath:
Callon Petroleum Company (NYSE:CPE)
Callon Petroleum Company (CPE), declared the closing of its formerly confirmed underwritten public offering of 10,350,000 shares of its ordinary stock, counting 1,350,000 shares sold to the underwriter following its option to purchase additional shares, which the underwriter exercised in full on March 12, 2015. Following this issuance, Callon now has 65,931,941 shares of ordinary stock issued and outstanding. Total net proceeds of the offering, after underwriting discounts and estimated offering expenses, will be about $65.7 million.
Callon intends to use the net proceeds from this offering to repay amounts outstanding under its credit facility, with any remainder being used for general corporate purposes, which may comprise funding of its capital program and future attainments.
Callon Petroleum Corporation engages in the exploration, development, attainment, and production of oil and natural gas properties in the Permian Basin in West Texas.
Cytori Therapeutics, Inc. (NASDAQ:CYTX)
Cytori Therapeutics, Inc. (CYTX), declared its fourth quarter and year end 2014 business and financial results.
By virtue of widespread cost reduction initiatives implemented in 2014, Cytori achieved substantial influence in tapering operating cash burn. Q4 operating cash burn reduced to $4.9 million, down from $7.2 million in Q3 2014, and $9.5 million a year ago in Q4 2013. We will continue to work to drive down expenses and raise operating efficiencies, and expect to deliver year-over-year operating cash burn savings of about $10 million from 2013 to 2015. Specifically, the predictable operating cash burn in 2015 will be about $25 million for the year, down from $35 million in 2013. 2014 cost reduction efforts have comprised of eliminating and consolidating certain commercial and development activities and containing outside professional services. Going forward, additional cost reductions will be derived primarily from changes to our fixed costs and physical locations. These efforts will be complemented by diligently working with Cytori’s lenders to restructure and extend debt obligations.
Cytori achieved total proceeds for the year and fourth quarter ended December 31, 2014 of $7.6 million and $3.8 million, respectively, contrast to $12.2 million and $3.5 million, respectively, for the same periods in 2013. Total net loss allocable to ordinary stock holders was $38.5 million in 2014 contrast with $26.2 million in 2013. Cytori ended the year with $14.6 million of cash and cash equivalents.
In addition, Cytori received recently written notification from the NASDAQ Stock Market LLC that it has regained full compliance with the NASDAQ Stock Market Listing Rules concerning the Corporation’s closing bid price, and formerly received written notification indicating the Corporation regained compliance with the NASDAQ Stock Market Listing Rule regarding the market value of listed securities. The Corporation is happy that each of the NASDAQ Stock Market compliance issues we formerly stated in the latter part of 2014 have been resolved.
Cytori Therapeutics, Inc., a cell therapy corporation, develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made accessible to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products.
CorMedix, Inc. (NYSEMKT:CRMD)
Formerly on March 9, CorMedix, Inc. (CRMD), declared that the extension to April 30, 2015 of the expiration date applies to all publicly traded warrants.
The holders of CorMedix warrants should note that the Corporation issued two tranches of warrants in 2010 with the same CUSIP number (No.21900C118). The first tranche of warrants were purchased for cash in connection with the Corporation’s initial public offering of ordinary stock in 2010, and may be exercised at the specified exercise price in exchange for registered, freely tradable shares of ordinary stock issued following a presently effective registration statement.
The second tranche of warrants was also issued in 2010 to a select group of investors in exchange for debt issued preceding to the Corporation’s initial public offering. The holders of these warrants may exercise and receive in exchange shares of unregistered ordinary stock. The Corporation intends to file a registration statement for the resale of the shares issuable upon exercise of the second tranche of warrants as soon as practicable following the filing later this week of the Corporation’s Annual Report Form 10-K.
The exercise date for both tranches of warrants, inclusive of all publicly traded warrants, has been extended from March 24, 2015 to April 30, 2015.
CorMedix Inc., a pharmaceutical corporation, intends to in-license, develop, and commercialize therapeutic products for the prevention and treatment of cardiac, renal, and infectious diseases. CorMedix’s first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients counting neonates, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications.
Whiting Petroleum Corp. (NYSE:WLL)
Formerly on March 4, Whiting Petroleum Corp. (WLL), declared the results of its offer to purchase for 101% of par, plus accrued and unpaid interest to the payment date (the “offer”), all of the following notes originally issued by Kodiak Oil & Gas Corp.: $800.0 million aggregate principal amount of 8.125% Senior Notes Due 2019, $350.0 million aggregate principal amount of 5.500% Senior Notes Due 2021 and $400.0 million aggregate principal amount of 5.500% Senior Notes Due 2022. Whiting was required to make the offer as a result of its attainment of Kodiak on December 8, 2014.
Whiting Petroleum Corporation, an independent oil and gas corporation, attains, explores, develops, and produces crude oil, natural gas liquids, and natural gas in the Rocky Mountains and Permian Basin regions of the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
